Cipla Shifting Focus From Volume To Profitability For Sales Growth
This article was originally published in PharmAsia News
Executive Summary
Cipla for the past few months has been undergoing a transition from the drug maker under Yusuf Hamied making HIV/AIDS drugs affordable in developing countries to a firm run by others who are leading it into new territories.